Major Brokerage Firms Issue Research Notes on Vir Biotechnology Inc. (VIR)

Vir Biotechnology Inc. (NASDAQ:VIR) saw an upside of 8.07% to close Monday at $40.02 after adding $2.99 on the day. The 5-day average trading volume is 997,620 shares of the company’s common stock. It has gained $40.27 in the past week. An average of 1,101,690 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,080,800.

VIR’s 1-month performance is -22.59% or -$11.68 on its low of $32.61 reached on 10/04/21. The company’s shares have touched a 52-week low of $25.31 and high of $141.01, with the stock’s rally to the 52-week high happening on 01/27/21. YTD, VIR has achieved 49.44% or $13.24. However, the current price is down -71.62%% from the 52-week high price.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

On Oct 06, 6 days have gone by since the last insider trading activity for Vir Biotechnology Inc. (VIR). Pang Phillip (Chief Medical Officer) most recently sold 5,000 shares at $34.56 per share on Oct 06. This transaction cost the insider $172,780. EVP, Research & CSO, Virgin Herbert, sold 1,375 shares at a price of $33.75 on Oct 05. Then, on Sep 21, EVP, Research & CSO Virgin Herbert sold 4,125 shares at a price of $50.00 per share. This transaction amounted to $206,250.

Valuation Metrics

Vir Biotechnology Inc. (VIR) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.VIR stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 26.71 while the price-to-book (PB) in the most recent quarter is 7.06.

Vir Biotechnology Inc.’s quick ratio for the period ended June 29 was 5.90, with the current ratio over the same period at 5.90 meaning that VIR stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00. In terms of profitability, the gross margin trailing 12 months is 99.40%. The trailing 12-month EBITDA margin is -376.25%. The firm’s gross profit as reported stood at $373.35 million against revenue of $76.37 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Vir Biotechnology Inc.’s cash and short-term investments amounted to $84.11 million against total debt of $72.46 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected VIR to announce -$0.48 per share in earnings in its latest quarter, but it posted $0.46, representing a 195.80% surprise. EBITDA for the quarter stood at more than $61.77 million. VIR stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 320.26 million, with total debt at $72.46 million. Shareholders hold equity totaling $130.61 million

Technical Picture

Let’s look briefly at Vir Biotechnology Inc. (VIR) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 48.15% to suggest the stock is trending Neutral, with historical volatility in this time period at 141.12%.

The stock’s 5-day moving average is $36.09, reflecting a +17.57% or $5.98 change from its current price. VIR is currently trading -19.75% above its 20-day SMA, -8.98% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +12.26% and +27.49% respectively.

Stochastic %K and %D was 25.38% and 15.35% and the average true range (ATR) pointed at 3.19. The RSI (14) points at 45.46%, while the 14-day stochastic is at 43.74% with the period’s ATR at 3.16. The stock’s 9-day MACD Oscillator is pointing at -0.07 and -2.64 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Vir Biotechnology Inc. (NASDAQ: VIR), Goldman downgraded it to a Neutral rating. They previously had a Buy rating on the stock. Analysts offering their rating for VIR stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate VIR as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 5 have offered a “buy” rating.

What is VIR’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $29.00 and a high of $135.00, with their median price target at $65.00. Looking at these predictions, the average price target given by analysts is for Vir Biotechnology Inc. (VIR) stock is $68.14.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam